Aim: Omentin-1, as a novel adipocytokine, ameliorates obesity-associated disorders and suppresses the development of atherosclerotic lesions. The present research investigated the correlation between serum omentin-1 and post-infarction myocardial function.
Introduction
Early reperfusion strategies and adjuvant pharmacological therapies limit myocardial injury and improve survival after ST-segment elevation myocardial infarction (STEMI) 1, 2) . However, reperfusion itself can induce additional damage to ischemic myocardium termed myocardial ischemia/reperfusion (I/R) injury, which also contributes to negative post-infarction myocardial remodeling and subsequent heart dysfunction 3, 4) . Recently, clinical and experimental studies have indicated that the novel adipocytokine omentin-1 plays an important role in regulating I/R injury 5) .
Omentin-1, also named intelectin-1, is a novel adipocytokine with 313 amino acids, which is predominantly secreted by the human visceral adipose tissue rather than subcutaneous adipose tissue 6, 7) . Serum omentin-1 declines significantly in patients with obesity and obesity-associated disorders, including impaired glucose regulation, type 2 diabetes mellitus, and metabolic syndrome [7] [8] [9] . Serum levels of omentin-1 are also downregulated in patients with coronary artery disease (CAD) 10, 11) , and upregulated in patients with the acute coronary syndrome (ACS) 12, 13) . Additionally, serum omentin-1 not only suppresses the process of atherosclerotic lesions 13, 14) but also may represent a novel biomarker inversely correlated with plaque instability 15) . Furthermore, serum omentin-1 also ameliorates myocardial damage and myocardial function after successful reperfusion in patients with STEMI 5) .
However, there is no previous research concerning the kinetic changes in omentin-1 during the acutephase of STEMI and the influence of it on myocardial damage and function after reperfusion. Therefore, the main purpose of this study was to address the correlations among the admission omentin-1, time-dependent kinetic changes in omentin-1, and myocardial function in patients with STEMI after successful primary percutaneous coronary intervention (PCI).
Methods

Subjects and Study Design
Between June 2017 and May 2018, patients with anterior STEMI were recruited from two hospitals in Beijing, China. Inclusion criteria were age 18 years, typical symptoms 30 minutes and 12 hours, electrocardiogram sign (ST-segment elevation 2 mm in at least two contiguous precordial leads or 1 mm in at least two contiguous limb leads), the infarct-related artery being the left anterior descending (LAD) artery and 70% stenosis of the non-infarct-related artery treated successfully by primary PCI. The success of primary PCI was defined as the recanalization of the LAD 
Statistical Analysis
Normality distribution of continuous variables was assessed by Kolmogorov -Smirnov test. Continuous data are expressed as the mean standard deviation or median value with interquartile range. Mean values of the data were compared by independent-sample t -tests but median values of variables were compared by the Mann -Whitney U test. Categorical variables are presented as percentages and were analyzed by chi-squared tests. Oneway analysis of variance was used to test the trend of time course of serum omentin-1. The association between variables was assessed by Pearson correlation coefficients. In addition, the associations between variables and LVEF change from baseline to 3 months were determined by univariate analysis and multivariate linear regression analysis. All the statistical analyzes were performed using SPSS 20.0 software (SPSS Inc., Chicago, IL, USA). P values 0.05 were considered statistically significant.
Results
Baseline Characteristics
The baseline characteristics of patients recruited into this study are presented in Table 1 . The mean age of the recruited patients was 55.12 12.43 years old, and 76.9% were male. The prevalence of current smoker, hypertension, and diabetes were 73.1%, 51.9%, and 19.2%, respectively. In addition, peak CK -MB was 217.82 141.8 U/L and the median NT-proBNP at day 3 post-STEMI was 494.50 (249.25, 1610.00) pg/ ml. Furthermore, 67.3% of the recruited patients had single vessel disease. Most importantly, the mean total ischemic time was 359.88 206.47 minutes, which revealed that all the patients recruited obtained timely reperfusion. We also divided the patients into two subgroups. Except for peak CK -MB, NT-proBNP, and (TNF-) and interleukin-6 (IL-6). The concentrations of serum omentin-1 and inflammatory cytokines were measured in duplicate by commercially available enzymelinked immunosorbent assay (ELISA) kits according to the manufacturer's instructions (BLUE GENE, Shanghai, China). Both ELISA intra-assay and inter-assay coefficients of variation in our study were 5%. Finally, we defined (admission omentin-1 level) -(serum omentin-1 at 24 hours after admission) as 1 and (admission omentin-1 level) -(serum omentin-1 at 72 hours after admission) as 2.
Peak MB fraction of creatine kinase (CK -MB) correlated well with infarct size and prognosis after acute myocardial infarction 16) . Thus, CK -MB levels were measured on admission, the following evening, and morning to identify peak CK -MB. N-terminal pro-B-type natriuretic peptide (NT-proBNP) measured 2 to 4 days following STEMI independently forecast myocardial function and 2-year survival, which is superior to BNP and other cardiac peptides 17, 18) . So, NT-proBNP at day 3 post-STEMI was determined. The rest of the routine biochemical parameters were also determined in the Central Laboratory of Beijing Anzhen Hospital.
Evaluation of Myocardial Function with Echocardiography
Doppler echocardiography was performed by the same two experienced doctors at 2 days and 3 months post-STEMI. Standard echocardiography views were obtained with the supervision of experienced cardiologists. Left ventricular ejection fraction (LVEF) was acquired with the modified Simpson biplane method. The change in LVEF was regarded as (LVEF at 3 months post-STEMI) -(LVEF at 2 days post-STEMI).
(Cont. Data are presented as Mean SD, median (low quartile ,upper quartile), or number (%) BP blood pressure, LVEF left ventricular ejection fraction, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, CK-MB muscle brain fraction of creatine kinase, NT-proBNP N-terminal pro B-type natriuretic peptide, LAD left anterior descending coronary artery, TIMI thrombolysis in myocardial infarction, PCI percutaneous coronary intervention, AMI acute myocardial infarction, ACEI/ARB angiotensin-converting enzyme inhibitor/angiotensin receptor blocker change in LVEF from baseline to 3 months, no significant differences were observed between the two subgroups.
Change in Serum Omentin-1 in Acute STEMI
The sequential change in serum omentin-1 concentration in the recruited patients was tested first. The mean concentration of serum omentin-1 on admission, at 24 hours, and at 72 hours after admission was 934.75 249.82 pg/ml, 833.87 197.27 pg/ml and 844.80 220.80 pg/ml, respectively (p trend 0.044). As indicated in Fig. 1A , admission omentin-1 was the highest, while omentin-1 declined rapidly the following 72 hours. Additionally, as shown in Fig. 1B and Fig. 1C , baseline serum omentin-1 positively correlated with 1 (r 0.626, p 0.001) and 2 (r 0.473, p 0.001).
Serum Omentin-1 and Inflammatory Cytokine Analysis
Correlation between serum omentin-1, time-dependent change in omentin-1, and inflammatory markers are presented in Table 2 . For admission omentin-1 with inflammatory cytokines, admission omentin-1 not only correlated positively with admission IL-6 (r 0.786, p 0.001) and admission TNF-(p 0.565, p 0.001) but also correlated positively with IL-6 and TNFat other time points. In addition, omentin-1 concentration at 24 and 72 hours after admission also had consistent correlation with inflammatory cytokines at each time point. Furthermore, there were consistent correlations between 1 and IL-6 on admission (r 0.519, p 0.001), at 24 hours (r 0.421, p 0.002), and at 72 hours (r 0.489, p 0.001) after admission. 1 also correlated with admission TNF-(r 0.362, p 0.008) and TNF-at 72 hours (r 0.275, p 0.048) after admission. For 2, there were also positive correlations with IL-6 on admission (r 0.294, p 0.034) and at 24 hours (r 0.297, p 0.033) after admission.
Association between Omentin-1 and Peak CK -MB with NT-proBNP
As shown in Table 1 , compared with the low admission omentin-1 group, the high admission omentin-1 subgroup had a lower level peak CK -MB (178.05 126.12 U/L vs. 257.58 147.75 U/L, p 0.042). As shown in Fig. 2A and Fig. 2B , there were inverse correlations between 1 (r 0.280, p 0.044), 2 (r 0.294, p 0.034) and peak CK -MB. Additionally, as presented in Table 1 , the patients in the subgroup with high admission omentin-1 also exhibited a lower NT-proBNP level [426.00 (206.50, 918.25) pg/ml vs. 1040.00 (409.75, 1940.75) pg/ml, p 0.008] measured at 3 days post-STEMI. As revealed in Fig. 2C and Fig. 2D , there were also negative correlations between 1 (r 0.384, early improvement of myocardial function in patients with their first anterior STEMI after primary PCI. In the present study, we demonstrated several relationships. First, serum omentin-1 was the highest on admission but declined significantly in the following 72 hours. Additionally, admission omentin-1 level correlated positively with time-dependent kinetic changes in omentin-1 level ( 1 and 2). Second, peak CK -MB and NT-proBNP at 72 hours post-STEMI were significantly lower in the high admission omentin-1 subgroup. Additionally, the high admission omentin-1 group improved markedly in the change in LVEF compared to the low omentin-1 group. Third, time-dependent kinetic changes in omentin-1 level ( 1 and 2) had negative correlations with peak CK -MB and NT-proBNP at 72 hours post-STEMI. Furthermore, the 1 and 2 not only correlated positively with LVEF at 3 months post-STEMI but also correlated with the change in LVEF. Accumulating evidence indicated omentin-1, as a novel adipocytokine with cardioprotective effects, is downregulated in people with atherosclerosis and risk factors associated with atherosclerosis, including obesity, diabetes, hypertension, and dyslipidemia 7, 19, 20) . Watanabe et al. and Du et al. further revealed that the concentration of omentin-1 was declined in the serum, epicardial adipose tissue and coronary endothelium in patients with CAD 11, 13) . However, the omentin-1 concentration increased markedly in the medial layer vascular smooth muscle and macrophage-derived foam cells within advanced plaques and circulating blood in patients with ACS 13) . Saddic et al. and Kadoglou et al. further showed that serum omentin-1 increased significantly after acute myocardial ischemia 12, 21) . All these evidence suggests that serum omentin-1 not only was a passive risk factor for chronic CAD but was also an acute-phase reactant with cardioprotective effects during ACS. In addition, metformin may raise serum omentin-1 level in patients with acute myocardial infarction (AMI) and decrease the serum cardiac troponin concentration 22) . Weight loss, statin, and other hypoglyce-p 0.005), 2 (r 0.420, p 0.002) and NT-proBNP measured at 3 days post-STEMI.
Correlation between Omentin-1 and the Early Change in Myocardial Function
After calculating the change in LVEF from baseline to 3 months post-STEMI, as shown in Fig. 3A , our data demonstrated that the absolute change in LVEF improved significantly in the high admission omentin-1 group compared to the low admission omentin-1 group (5.27% 7.11% vs. 0.46% 7.84%, P 0.008). Additionally, as indicated in Fig. 3B , the global LVEF in the high admission omentin-1 group improved significantly (59.41% 7.23% vs. 54.15% 7.73%, p 0.014), but the low admission omentin-1 group was without such improvement (55.96% 8.84% vs. 56.42% 6.71%, p 0.833).
As for the time-dependent change in serum omentin-1 with LVEF at 3 months post-STEMI, there were moderate correlations between 1 (r 0.392, p 0.004), 2 (r 0.382, p 0.005), and LVEF at 3 months post-STEMI ( Fig. 4A, Fig. 4B ). Most importantly, moderate but high associations were also observed between 1 (r 0.346, p 0.012), 2 (r 0.439, p 0.001), and change in LVEF from baseline to 3 months post-STEMI ( Fig. 4C, Fig. 4D ). Last but not the least, in multivariate linear regression model, which included age, sex, and other variables with p 0.05 in univariate analysis as shown in Table 3 , 1 (Beta 0.026, 95% CI 0.011 to 0.041, p 0.001) remained associated with the absolute change in LVEF from baseline to 3 months post-STEMI in multiple linear regression model A. Additionally, in model B, 2 (Beta 0.024, 95% CI 0.009 to 0.038, p 0.003) also correlated with the change in LVEF from baseline to 3 months post-STEMI.
Discussion
This is the first study to manifest time-dependent kinetic changes in omentin-1 levels associated with the ing blood in patients with ACS 12, 13, 21) . Our present study extends prior findings by indicating that increased admission omentin-1 declined transiently during the acute-phase of STEMI. The accumulation of omentin-1 in injured cardiovascular tissues as suggested by in vivo and in vitro experiments may 13) , at least in part, account for the post-procedural transient decrement of serum omentin-1. Additionally, in patients with STEMI, the baseline adiponectin also decreased transiently, maybe due to the accumulation of adiponectin in injured cardiovascular tissues mediated by T-cadherin [29] [30] [31] [32] . Thus, this study calls for a future study to determine the mediators that play a critical role in cardiovascular tissue accumulation of omentin-1. Kataoka et al. showed that high levels of circulating omentin-1 in mice limited myocardial injury and mic agents, such as liraglutide and exenatide, may also increase serum omentin-1 level [23] [24] [25] [26] , but the evidence in patients with AMI was limited.
As we all know, myocardial I/R injury is characterized by an acute level of high-grade inflammatory response with rapid formation and release of TNFand IL-6 27, 28) . In our present study, anti-inflammatory mediator omentin-1 correlated positively with the two key cytokines, TNFand IL-6, during the acute-phase of STEMI. Therefore, our study further confirmed that omentin-1 may act as an acute-phase reactant to counteract the inflammatory response for the sake of cardiovascular protection during the process of myocardial I/R. Now, accumulating evidence has indicated that baseline omentin-1 increased significantly in circulat- Watanabe et al. showed through in vivo and in vitro experiments that almost all exogesly infused omentin-1 accumulated in the injured cardiovascular tissue, including the adventitia tissue of the aorta, myocardium and macrophages, without significant change in serum omentin-1 levels 13) . In STEMI patients, examination of the accumulation of omentin-1 in the infarct region was impossible, but a transient decrement of serum omentin-1 in STEMI patients may imply the accumulation of omentin-1 in the infarct region. The myocardial infarction size 5) . In our present study, we have shown that in patients with STEMI, peak CK -MB also declined significantly in the subgroup with a high level of admission omentin-1. Natsukawa et al. reported that the transient decrement of adiponectin from baseline to bottom during acute-phase STEMI was significantly associated with the area under the curve of CK -MB 30) . In our present study, both 1 and 2 also correlated negatively with peak CK -MB. Subsequently, we found the absolute change in LVEF from baseline to 3 months post-STEMI improved significantly in patients with a high level of baseline omentin-1. Similar to our finding, Kataoka et al. also confirmed that high levels of serum omentin-1 in post-STEMI patients were correlated with the improvement of myocardial function 5) . Most importantly, our study demonstrated that time-dependent changes in omentin-1, 1, and 2 correlated positively with the improvement of myocardial function for the first time. In addition, as Narumi et.al reported, high baseline omentin-1 level may have beneficial effects on cardiac prognosis in patients with heart failure or reduced LVEF 33) , whereas the effects of timedependent change in omentin-1 in patients with heart failure were unknown.
Omentin-1 not only stimulated vasodilation of the isolated aorta via endothelium-dependent NO but also improved endothelial cell function and the process of revascularization in circumstances of acute ischemia via the AKt/eNOS pathway 34, 35) . For the antiinflammatory effect, omentin-1 stimulated the differentiation of macrophages into the M2 phenotype exerting an overwhelming anti-inflammatory action, rather than the M1 phenotype with proinflammatory action 13) . In addition, omentin-1 attenuated the vascular inflammatory response via various kinds of intracellular signaling pathways [36] [37] [38] . Therefore, the anti-inflammatory and modulation of endothelial function features may account, at least in part, for omentin-1 being protective against I/R injury. In addition to myocardial infarction, other forms of cardiomyocyte death, including apoptosis, autophagy, and necroptosis were also responsible for the final infarct size and myocardial dysfunction in the post-STEMI patients 3) . Omentin-1 can suppress the apoptosis of the myocyte associated with I/R via the mutually independent AMPK and Akt signal pathways, which was also responsible for the improvement in myocardial damage and function post-STEMI 5) . Whether omentin-1 has an influence on autophagy and necroptosis calls for further study. Furthermore, the cross talk between omentin-1 and other adipocytokines may also participate in regulating myocardial necrosis and subsequent myocardial remodeling, which needs further confirmation by large-scale clinical studies and in vitro experiments 12, 39) . up a novel therapeutic window for I/R injury.
Study Limitations
There are several limitations to this study. First, this was a cross-sectional study with a relatively small sample size. To further elucidate the relationship between time-dependent kinetic changes in omentin-1 level and the recovery of myocardial function large scale clinical studies are required. Second, we only enrolled patients with first anterior STEMI who underwent primary PCI, which may affect the outcome because we may have missed some critical STEMI patients. Third, the LVEF was only assessed by Doppler echocardiography, future studies should apply cardiac magnetic resonance imaging or single-photon emission computed accumulation of omentin-1 in the infarct region may exert cardioprotective effects. As shown in Fig. 2 and  Fig. 4 , a transient decrement of serum omentin-1 ( 1 and 2) not only had inverse correlation with peak CK -MB and NT-proBNP at 72 hours post-STEMI, but also correlated positively with LVEF at 3 months post-STEMI and the early improvement in LVEF, suggesting the possibility that accumulation of omentin-1 may reduce myocardial necrosis and improve postinfarction myocardial function.
In our present study, admission omentin-1 and inflammatory cytokines (TNFand IL-6) all have positive effects on the cardiovascular tissue accumulation of omentin-1. If we can identify the mediators that play a critical role in cardiovascular tissue accumulation of omentin-1 during I/R injury, we may open myocardial function. Our data suggested that omentin-1 is a novel adipocytokine that suppresses myocardial I/R injury and subsequent negative remodeling. Future studies are warranted to further elucidate the underlying mechanism between omentin-1 and myocardial I/R injury as well as subsequent negative remodeling. In addition, identifying the key mediators regulating cardiovascular tissue accumulation of omentin-1 is also very important.
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We convey thanks to the following doctors, Meng Li, Kun Wang, Xue-Jie Wang, and Jie Sun for their help in collecting the blood sample. This work was supported by the Beijing Municipal science and Technology Commission (NO. Z171100000417042). tomography imaging to assess LVEF exactly and quantify the infarct size. Fourth, our research failed to determine whose omentin-1 levels might be lower before the onset of AMI, which needs further investigation by future research. Finally, after multiple linear regression analysis, 1 and 2 remained associated with the absolute change in LVEF from baseline to 3 months post-STEMI. However, the influence of residual confounding variables cannot be excluded.
Conclusions
In patients with their first anterior STEMI who underwent primary PCI, the early recovery of postinfarction myocardial function were significantly associated with admission omentin-1 levels and the timedependent change in serum omentin-1. Through multivariate linear regression analysis, only the time-dependent change in omentin-1 ( 1 and 2) remained associated with the early improvement of post-infarction LVEF left ventricular ejection fraction, CI confidence interval , FBG fasting blood-glucose, HDL high-density lipoprotein, 1 as (omentin-1 leve1 on admission) -(omentin-1 level at 24 hours after admission), IL-6 interleukin-6, TNFtumor necrosis factor-alpha, 2 as (admission omentin-1 level)-(omentin-1 level at 72 hours after admission).
